# A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

> **NCT02198170** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ketoconazole-placebo
- **DRUG:** placebo-ketoconazole

## Key facts

- **NCT ID:** NCT02198170
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198170, "A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02198170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*